CAR-T cells have shown incredible clinical potential in certain hematological malignancies but the technology faces significant challenges that limits its use. Overcoming these hurdles to expand the use of CAR-T cells has the potential to revolutionize medicine. In this video I explore the history of CAR-T and lay out the 4 major hurdles that the technology faces today.
About 85% of cancer immunotherapies, such as cancer vaccines, checkpoint inhibitors, and CAR-T cells, target T cell biology due to their potent cytotoxic abilities. However, T cell therapies often cause significant toxicities. Natural killer (NK) cells present a safer alternative but lack the expansive power of T cells, limiting their therapeutic potential. Innate Pharma has developed an NK cell engager that may overcome this limitation, unlocking NK cell therapy for cancer treatment.
Video description T cell exhaustion can severely hinder anti-cancer immune responses and several therapeutic modalities – including the most successful drug in medicine Merck’s KEYTRUDA – are designed to combat it. A paper published in Nature Immunology on November 8th…
In recent years, immune checkpoint inhibitors have dominated the healthcare landscape. In fact, last year, Merck's PD-1 mAb KEYTRUDA was the most successful drug in all of medicine. However, a new wave of medicine is on the horizon that is threatening to topple Merck's oncology kingdom and usurp KEYTRUDA's throne. Multi-specific protein therapeutics - bispecific antibodies being the most popular.
Description Last week, Autolus announced that they had received FDA approval for their autologous CAR-T cell therapy obe-cel (AUCATZYL) for use in adult r/r B-ALL. This is amazing news for the patients and the company – congrats to both! In…
